Researchers at the University of Tokyo's Center for Advanced Science and Technology have developed a vaccine that is expected to be effective against the Nipah virus. The first phase of human trials will begin in April, SİA reports citing Nikkei newspaper.
The vaccine is based on the measles virus. When administered to the human body, it should stimulate the production of proteins similar to those of the Nipah virus, which will strengthen the immune system and potentially protect against further infection should the virus be contracted.
Scientists at the University of Tokyo have already confirmed the vaccine's efficacy and safety in trials on hamsters and other animals. The first phase of human trials will begin in April in Belgium. If successful, subsequent phases of safety and efficacy trials in adults and children will begin in Bangladesh in the second half of 2027.
Funding for the vaccine development and testing is provided by SCARDA, the Japanese government's advanced research and development center, which coordinates vaccine development in Japan.
Bütün xəbərlər Facebook səhifəmizdə
.jpg)
.jpg)
.jpg)
.png)
.jpg)
USD
EUR
GBP
RUB